EyePoint Pharmaceuticals/$EYPT
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About EyePoint Pharmaceuticals
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
- Ticker
- $EYPT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- Watertown, United States
- Website
- eyepoint.bio
EYPT Metrics
BasicAdvanced
$272M
-
-$3.76
1.64
-
Price and volume
Market cap
$272M
Beta
1.64
52-week high
$19.11
52-week low
$3.05
Average daily volume
3.6M
Financial strength
Current ratio
4.502
Quick ratio
4.305
Long term debt to equity
0.119
Total debt to equity
0.135
Interest coverage (TTM)
-9,605.33%
Profitability
EBITDA (TTM)
-314.376
Gross margin (TTM)
-9,164.20%
Net profit margin (TTM)
-10,998.67%
Operating margin (TTM)
-11,369.30%
Effective tax rate (TTM)
-0.04%
Management effectiveness
Return on assets (TTM)
-74.85%
Return on equity (TTM)
-148.70%
Valuation
Price to revenue (TTM)
92.043
Price to book
1.61
Price to tangible book (TTM)
1.61
Price to free cash flow (TTM)
-0.946
Free cash flow yield (TTM)
-105.72%
Free cash flow per share (TTM)
-3.33
Growth
Revenue change (TTM)
-94.63%
Earnings per share change (TTM)
38.85%
3-year revenue growth (CAGR)
-57.89%
3-year earnings per share growth (CAGR)
9.97%
What the Analysts think about EYPT
Analyst ratings (Buy, Hold, Sell) for EyePoint Pharmaceuticals stock.
Analyst projections of the future price of EyePoint Pharmaceuticals stock.
EYPT Financial Performance
Revenues and expenses
EYPT Earnings Performance
Company profitability
Upcoming events
No upcoming events
EYPT News
AllArticlesVideos
EYPT SHAREHOLDER ALERT: EyePoint Pharmaceuticals Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
Business Wire1 month ago
EYPT Investors Have Opportunity to Join EyePoint, Inc. Fraud Investigation with SBS Law
Business Wire1 month ago
NASDAQ: EYPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages EyePoint, Inc. (NASDAQ: EYPT) Investors to Contact the Firm
Business Wire1 month ago
Funds containing EYPT
AllUSDEURGBP
Fund name | Fund size | $EYPT weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.02% |
iShares Ageing Population€AGED | €822M | 0.02% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.02% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.